

ICB-0-3

Carcinoma, infiltrating duct, NOS 8500/3

Site: Breast, NOS C50.9 12/11/11

Procedure Date:

Procedure Physician:

Attending Physician/Copies To:

UUID:E66D3DF8-1605-4EFD-AAFA-74F82366FD16
TCGA-BH-A1ET-01A-PR

Redacted

PATIENT HISTORY:

* DATE OF LMP: *

DATE OF LAST DELIVERY: *

PRE-OP DIAGNOSIS: CANCER LEFT BREAST

POST-OP DIAGNOSIS: SAME

OPERATIVE PROCEDURE: LEFT SEGMENTAL MAST, LEFT AXILLARY DISS

CLINICAL HISTORY: *

MATERIAL SUBMITTED: A) LEFT BREAST BIOPSY/MASS/SEGMENTAL MASTECTOMY, PROCUREMENT BY SURGICAL PROCEDURE

B) LEFT AXILLARY LYMPH NODE(S), PROCUREMENT BY SURGICAL PROCEDURE

ADDENDA:

Addendum

MACROSCOPIC DESCRIPTION: Block "A2" for ER/PR and HER-2/neu

FINAL DIAGNOSIS:

ER/PR RESULTS

IMMUNOPEROXIDASE IDENTIFICATION OF ESTROGEN AND PROGESTERONE RECEPTORS IS CARRIED OUT ON SLIDE "A2". DISTINCT INTRANUCLEAR STAINING IS IDENTIFIED FOR ESTROGEN RECEPTOR (95%) AND PROGESTERONE RECEPTOR (80%). THEREFORE, BOTH ARE INTERPRETED AS POSITIVE.

HER-2/NEU RESULTS

AS PER THE REQUEST OF DR. RAFFONI, c-erbB2 (HER-2/NEU) IMMUNOSTAINING IS CARRIED OUT ON PREVIOUS MAGEE BLOCK "A2" (BREAST CANCER) USING A 1:300 DILUTION OF DAKO'S POLYCLONAL ANTIBODY A485 (DIRECTED AGAINST THE INTRACELLULAR DOMAIN OF c-erbB2) WITHOUT ANTIGEN RETRIEVAL. NO DISTINCT COMPLETE MEMBRANE STAINING IS IDENTIFIED. THEREFORE, c-erbB2 (HER-2/NEU) IS INTERPRETED AS NEGATIVE (SCORE 0).

FINAL DIAGNOSIS:

FINAL DIAGNOSIS:

A) LEFT BREAST, SEGMENTAL MASTECTOMY:

- INFILTRATING MODERATELY DIFFERENTIATED DUCT CARCINOMA WITH FOCAL LOBIULAR FEATURES. 2.0 CM. (AS MEASURED ON GLASS SLIDE), POOR ARCHITECTURAL GRADE, INTERMEDIATE NUCLEAR GRADE (NOTTINGHAM SCORE=6, TUBULES=3, MITOTIC RATE=1, NUCLEAR PLEOMORPHISM=2) (SEE NOTE) (CROSS REFER

- FIBROCYSTIC CHANGES WITH ATYPICAL DUCTAL EPITHELIAL HYPERPLASIA

- PAPILLOMATOSIS WITH ASSOCIATED MICROCALCIFICATIONS

- MARGINS OF RESECTION ARE FREE OF TUMOR

B) LEFT AXILLARY CONTENTS:

- ONE OF NINETEEN (1/19) LYMPH NODES POSITIVE FOR METASTATIC CARCINOMA

NOTE: ER/PR immunoperoxidase assay and Her-2/NEU testing will be performed on block "A2".

Criteria	Yes	No
Diagnosis Discrepancy		
Primary Tumor Site Discrepancy		
HIPAA Discrepancy		
Print Mismatch		
Dual/Synchronous Primary Notes		
Case Is (circle):		
Reviewer Initials: <u>MD</u>		
Date Reviewed: <u>1/24/11</u>		